Clinical Trial Applications / CRO

Collaborating with researchers and pharmaceutical companies to harness the power of ElucidVivo

Unprecedented Insights from ElucidVivo Facilitate....

Risk-Based Clinical Trial Patient Inclusion/Exclusion

  • Accurately assess current plaque composition to determine if therapeutic would be appropriate based on parameters of therapeutic indications (e.g., exclude patients with little/no or too severe atherosclerosis, especially for immuno-oncology where plaque may rupture)

  • For disease types beyond cardiovascular (e.g., oncology), exclude patients at high risk of cardiovascular event

Expansion of Druggable Patient Population (2x-3x) For Approved Biologics

  • Measure statistically significant biological drug response 9+ months earlier than any other available technique, validating response for earlier treatment in broader patient population 

Development of Drugs For Early-Stage Disease Treatment

  • Capture statistically significant therapeutic response among patients with subclinical disease, enabling early treatment to slow and prevent progression towards interventional care

A Plausible Path to Market For Anti-Inflammatory Drugs to Treat CVD

  • Quantitative measures of CVD response to anti-inflammatories reveals systemic inflammation as a dominant mechanistic driver vs. circulating lipids - includes the first non-invasive measurements of cap thickness, quantity/proximity to LRNC to the lumen, and zinc homeostasis

Reduced Cost of Clinical Trials By Over 50%

  • Reduce the size of clinical trial patient population required to achieve clinical endpoint using quantitative inclusion/exclusion criteria based on MACE/stroke prediction diagnostic vs. non-specific patient suitability markers

Longitudinal Tracking of CVD Biomarkers and Drug Response

Study Example: 

Determine the efficacy of a drug in clinical trials or during patient care by tracking plaque progression or
regression over time

Longitudinal plaque regression of a patient in response to a therapeutic

Baseline

BEFORE CORONARY.png

1-Year Follow-Up

aFTER CORONARY.png
Calcification
Lipid Rich Necrotic Core

Source: “Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core.” Choi et al, 2020, Circulation

Partner With Us

To learn more about how ElucidVivo can enhance your clinical development process, please contact info@elucidbio.com. Our Sales and Clinical teams would look forward to discussing your needs and objectives. 

Notable Partnerships:

ki_logo_vert_rgb_Web_edited.jpg
amarin--600_edited.jpg
20201020-171420-UMMS.jpg
nih_logo_edited.jpg
output_edited.jpg